Molecular and Cellular Biology Program, University of Massachusetts-Amherst, Massachusetts, USA.
Stem Cells. 2011 Jan;29(1):119-27. doi: 10.1002/stem.552.
Breast cancer is the most common tumor among women with inherited mutations in the p53 gene (Li-Fraumeni syndrome). The tumors represent the basal-like subtype, which has been suggested to originate from mammary stem/progenitor cells. In mouse mammary epithelium, mammosphere-forming potential was increased with decreased dosage of the gene encoding the p53 tumor suppressor protein (Trp53). Limiting dilution transplantation also showed a 3.3-fold increase in the frequency of long-term regenerative mammary stem cells in Trp53-/- mice. The repression of mammospheres by p53 was apparent despite the absence of apoptotic responses to radiation indicating a dissociation of these two activities of p53. The effects of p53 on progenitor cells were also observed in TM40A cells using both mammosphere-forming assays and the DsRed-let7c-sensor. The frequency of long-term label-retaining epithelial cells was decreased in Trp53-/- mammary glands indicating that asymmetric segregation of DNA is diminished and contributes to the expansion of the mammary stem cells. Treatment with an inhibitor of γ-secretase (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) reduced the number of Trp53-/- mammospheres to the level found in Trp53+/+ cells. These results demonstrate that basal levels of p53 restrict mammary stem/progenitor cells through Notch and that the Notch pathway is a therapeutic target to prevent expansion of this vulnerable pool of cells.
乳腺癌是携带 p53 基因突变(Li-Fraumeni 综合征)的女性中最常见的肿瘤。这些肿瘤代表基底样亚型,据推测它起源于乳腺干细胞/祖细胞。在小鼠乳腺上皮中,p53 肿瘤抑制蛋白(Trp53)编码基因的剂量降低会增加乳腺球体形成的潜力。有限稀释移植也显示 Trp53-/-小鼠中具有长期再生乳腺干细胞的频率增加了 3.3 倍。尽管辐射诱导的凋亡反应缺乏,但 p53 对乳腺球体的抑制作用是明显的,表明 p53 的这两种活性是分离的。使用乳腺球体形成测定法和 DsRed-let7c-传感器,在 TM40A 细胞中也观察到 p53 对祖细胞的影响。Trp53-/-乳腺中长期标记保留上皮细胞的频率降低表明 DNA 的非对称分离减少,并有助于乳腺干细胞的扩增。γ-分泌酶抑制剂(N-[N-(3,5-二氟苯乙酰基)-L-丙氨酰]-S-苯甘氨酸叔丁酯)处理可将 Trp53-/-乳腺球体的数量减少到 Trp53+/+细胞中发现的水平。这些结果表明,基础水平的 p53 通过 Notch 限制乳腺干细胞/祖细胞,并且 Notch 途径是预防这种易扩张细胞池扩张的治疗靶标。